Evidence map›Paper›PMID 37081733›Full record

ArticleCancer medicine2023

Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.

Idoroenyi Amanam, Janny Yao, Alfredo Puing, Ni-Chun Tsai, Diana Samuels, Dat Ngo, Stephanie Ho, Haris Ali, Ahmed Aribi, Shukaib Arslan and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 1 institution in 1 country.

Idoroenyi AmanamDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0003-4819-4628
Janny YaoDepartment of Pharmacy, City of Hope National Medical Center, Duarte, California, USA.
Alfredo PuingDepartment of Infectious Diseases, City of Hope National Medical Center, Duarte, California, USA.
Ni-Chun TsaiDepartment of Computational and Quantitative Medicine, Division of Biostatistics, City of Hope National Medical Center, Duarte, California, USA.
Diana SamuelsDepartment of Pharmacy, City of Hope National Medical Center, Duarte, California, USA.
Dat NgoDepartment of Pharmacy, City of Hope National Medical Center, Duarte, California, USA.
Stephanie HoDepartment of Pharmacy, City of Hope National Medical Center, Duarte, California, USA.
Haris AliDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Ahmed AribiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Shukaib ArslanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0002-8447-9607
Andrew ArtzDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Myo HtutDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Paul KollerDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0003-3830-5320
Amandeep SalhotraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Karamjeet SandhuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Liana NikolaenkoDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Anna PawlowskaDepartment of Pediatrics, City of Hope National Medical Center, Duarte, California, USA.
Geoffrey ShouseDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0002-7917-5713
Anthony SteinDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Guido MarcucciDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Stephen FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Ryotaro NakamuraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Sanjeet DadwalDepartment of Infectious Diseases, City of Hope National Medical Center, Duarte, California, USA.
Monzr M Al MalkiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0001-8226-471X
City Of Hope National Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn November 2020, the FDA issued an emergency use authorization (EUA) for monoclonal antibody (mAb) therapy in patients with mild-to-moderate COVID-19 at high risk for disease progression.

methodsWe retrospectively reviewed 38 adult hematology patients who received mAbs from 11/2020 to 2/2021.

resultsThirty (79%) patients received bamlanivimab and 8 (21%) casirivimab-imdevimab. Four (11%) patients were hospitalized due to COVID-19, two (5%) progressed to severe disease and one patient (3%) died within 30 days from COVID-19 disease. Most patients (n = 34, 89%) ultimately tested negative for SARS-CoV-2, with 34% (n = 13) clearing the virus within 14 days after mAb infusion. The median time to clearance of viral shedding was 25.5 days (range: 7-138). After mAb infusion, most patients with hematological malignancies (HM) (n = 10/15; 67%) resumed therapy for underlying disease with a median delay of 21.5 days (range: 12-42). We observed a significant difference in hospitalization among patients who received a HCT versus non-HCT (0% n = 0/26 and 36% n = 4/11, respectively; p < 0.01).

conclusionsThis study demonstrates that SARS-CoV-2 specific mAb was safe and may reduce hospitalization compared to what is reported in malignant hematology patients at high risk for disease progression. Our HCT cohort patients had less hospitalization rate compared with HM cohort patients.

Indexed as

COVID-19Hematologic NeoplasmsHematologyAdultAntibodies, MonoclonalAntibodies, ViralDisease ProgressionHumansRetrospective StudiesSARS-CoV-2Antibodies, MonoclonalAntibodies, Viralcancer stem cellshematologic malignanciesleukemiatarget therapyviral infection

Identifiers

PMID37081733
PMCPMC10242327
OpenAlexW4366602987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.